What PharmaForce Inc. does

American Regent, Inc. (operating under the firmographic name PharmaForce Inc.) is a U.S.-based sterile injectable pharmaceutical manufacturer that operates as a wholly-owned subsidiary of Japan's Daiichi Sankyo Group. The company develops and produces a broad portfolio of USP-grade injectable medications spanning more than 40 stock-keeping units, including cardiovascular agents (HydrALAZINE, Nitroglycerin, Vasopressin, niCARdipine, Atropine), iron replacement therapies (Venofer iron sucrose, Injectafer ferric carboxymaltose), electrolyte and trace element solutions (Sodium Phosphates, Potassium Phosphates, Zinc Sulfate, Calcium Chloride, Tralement, Multrys), corticosteroids (Betamethasone), and specialty injectables such as antidotes (Fomepizole, ProvayBlue methylene blue), antipsychotics (Olanzapine, Droperidol), and supportive care products. American Regent also extends its manufacturing capability into animal health through a dedicated brand (aranimalhealth.com).

The company's business model is B2B institutional pharmaceutical distribution: products are sold to U.S. healthcare providers, hospitals, clinics, and pharmacies through a direct field sales representative motion and through authorized pharmaceutical distributors. Pricing is conducted via quote-based institutional contracts rather than disclosed price lists. Marketing channels rely on industry events, conferences, direct healthcare professional engagement, and a multi-line customer service infrastructure (customer service, adverse event reporting, product quality complaints, drug information). Operational differentiators center on the reliable supply of essential medicines — including drugs historically subject to shortage — and on the manufacturing scale provided by Daiichi Sankyo group backing. American Regent holds NABP Accredited Drug Distributor status and operates its corporate office from Shirley, New York, with the firmographic headquarters listed as New Albany, United States.

Name

PharmaForce Inc.

Legal name

American Regent, Inc.

Website

https://pharmaforceinc.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

American Regent, Inc. (operating as PharmaForce Inc.) is a Daiichi Sankyo subsidiary that manufactures and distributes 40-plus sterile injectable pharmaceuticals—including Venofer, Injectafer, Epinephrine, and electrolyte solutions—to U.S. hospitals, clinics, and pharmacies via direct field sales and authorized distributors.

Ownership category

akta.pro rank

Product category

Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Injectable pharmaceuticals
• Pharmaceutical manufacturing
• Critical care medications
• Iron deficiency therapy
• Parenteral nutrition

Headquarters

HQ city

New Albany

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Distribution channels1 record

Core offering

PharmaForce Inc., operating through its U.S. legal entity American Regent, Inc., develops, manufactures, and distributes a comprehensive portfolio of USP-grade injectable pharmaceutical products for human and animal health. The portfolio includes cardiovascular agents, iron replacement therapies, electrolyte and trace element solutions, antidotes, antipsychotics, corticosteroids, hormones, vitamins, and other specialty injectables sold primarily to healthcare facilities and authorized pharmaceutical distributors.

Product overview

American Regent is a pharmaceutical company that develops and manufactures injectable medications and essential medicines for human and animal health. The product portfolio includes a comprehensive range of USP-grade injectable pharmaceuticals including cardiovascular agents (HydrALAZINE, Nitroglycerin, Vasopressin, Atropine, niCARdipine), iron replacement therapies (Venofer iron sucrose, Injectafer ferric carboxymaltose), electrolyte solutions (Sodium Phosphates, Potassium Phosphates, Zinc Sulfate, Calcium Chloride), corticosteroids (Betamethasone), and various specialty injectables (Fomepizole, Droperidol, Olanzapine). The company also offers trace element combinations (Tralement, Multrys) and parenteral nutrition components. Products range from single-dose vials to multi-dose vials and pharmacy bulk packages in various concentrations. The portfolio is distributed through authorized pharmaceutical distributors.

Differentiator

Problem solved

Functional benefit

Products and services

• Epinephrine Injection, USP 30 mL multiple-dose vial formulation of epinephrine indicated for anaphylaxis and other emergency use, supplied to U.S. healthcare facilities.
• Sodium Phosphates Injection, USP Sodium phosphates injectable solution for phosphorus replacement therapy in U.S. clinical settings.
• Venofer (iron sucrose injection, USP) Iron sucrose injection for treatment of iron deficiency anemia, administered in U.S. healthcare facilities.
• Potassium Phosphates Injection, USP Potassium phosphates injectable solution for phosphorus and potassium replacement in U.S. clinical settings.
• HydrALAZINE Hydrochloride Injection, USP 20 mg/mL single-dose vial antihypertensive injection for hypertension management in U.S. healthcare facilities.
• Papaverine HCL Injection, USP 30 mg/mL, 2 mL single-dose vial smooth muscle relaxant injection for U.S. clinical use.
• Zinc Sulfate Injection, USP 5 mg/mL, 5 mL pharmacy bulk package vial injectable zinc supplement for treating zinc deficiency in U.S. clinical settings.
• Injectafer (ferric carboxymaltose injection) Ferric carboxymaltose injection for treatment of iron deficiency anemia, distributed to U.S. healthcare facilities.
• Tralement Trace elements injection for parenteral nutrition in U.S. clinical settings.
• Multrys Multi-trace elements injection for trace mineral supplementation in U.S. clinical settings.
• ProvayBlue (methylene blue) Injection USP Methylene blue injection for treatment of acquired methemoglobinemia, supplied to U.S. healthcare facilities.
• Gvoke VialDx Glucagon injection for treatment of severe hypoglycemia, supplied to U.S. healthcare facilities.
• niCARdipine Hydrochloride Injection USP Injectable calcium channel blocker for hypertension management in U.S. healthcare facilities.
• Olanzapine For Injection Antipsychotic injection formulation for U.S. clinical use.
• Droperidol Injection USP Butyrophenone antipsychotic and antiemetic injection for U.S. healthcare facilities.
• Hydroxyzine Hydrochloride Injection USP Antihistamine injection for anxiety and allergic conditions in U.S. clinical settings.
• Fomepizole Injection Antidote injection for methanol or ethylene glycol poisoning, supplied to U.S. healthcare facilities.
• Atropine Sulfate Injection, USP Anticholinergic injection for bradycardia and anticholinesterase poisoning in U.S. clinical use.
• Calcium Chloride Injection USP (10%) 10% calcium chloride injection for hypocalcemia and hyperkalemia in U.S. healthcare facilities.
• Levocarnitine Injection USP L-carnitine injection for treatment of carnitine deficiency in U.S. clinical settings.
• Vasopressin Injection USP Antidiuretic hormone injection for vasodilatory shock in U.S. healthcare facilities.
• Nitroglycerin Injection USP Vasodilator injection for acute heart failure and angina in U.S. clinical settings.
• Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension USP Corticosteroid injectable suspension for inflammatory conditions in U.S. healthcare facilities.
• Estradiol Valerate Injection, USP Estrogen hormone injection for U.S. clinical use.
• Cyanocobalamin (B12) Injection USP Vitamin B12 injection for treatment of B12 deficiency in U.S. clinical settings.
• Methylergonovine Maleate Injection USP Oxytocic agent injection for management of postpartum hemorrhage in U.S. healthcare facilities.
• Glycopyrrolate Injection USP Anticholinergic injection for reducing secretions and bradycardia in U.S. clinical settings.
• Acetylcysteine Solution USP Mucolytic and acetaminophen antidote injection for U.S. healthcare facilities.
• Aminocaproic Acid Injection USP Antifibrinolytic injection for bleeding management in U.S. clinical settings.
• Caffeine and Sodium Benzoate Injection USP CNS stimulant injection for apnea in premature infants in U.S. healthcare facilities.
• Chlorothiazide Sodium For Injection USP Thiazide diuretic injection for U.S. clinical use.
• Dicyclomine Hydrochloride Injection USP Anticholinergic injection for treatment of irritable bowel syndrome in U.S. clinical settings.
• Manganese Sulfate Injection USP Trace mineral injection for parenteral nutrition in U.S. healthcare facilities.
• Selenious Acid Injection USP Selenium supplement injection for total parenteral nutrition (TPN) in U.S. clinical settings.
• Sterile Water For Injection USP Diluent and solvent injection preparation used in U.S. healthcare facilities.
• Paclitaxel Protein-Bound Particles Antineoplastic agent injection for cancer treatment in U.S. healthcare facilities.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Baxter International: Baxter manufactures and supplies injectable and infusion pharmaceuticals to US hospitals and clinics; it competes in adjacent injectables and parenteral nutrition categories where American Regent also participates (e.g., TPN trace elements).
• Teva Pharmaceutical Industries: Teva's generics division includes a substantial US sterile injectable portfolio, positioning it as a broad incumbent competitor across many of the same generic injectable SKUs American Regent supplies.
• Sandoz (Novartis): Sandoz is the global leader in generic pharmaceuticals including a sizable sterile injectable portfolio serving US hospital customers, making it a broad incumbent peer to American Regent in generic injectables.
• Pfizer (Hospital / Injectables business): Pfizer's injectable portfolio (including the legacy Hospira assets) competes head-to-head with American Regent across a broad range of sterile injectables and is a dominant supplier to US hospitals and group purchasing organizations.

Direct peers

• Hospira (Pfizer): Now part of Pfizer, Hospira was the largest US sterile injectable manufacturer; its portfolio overlaps extensively with American Regent's hospital injectable products including cardiovascular, anesthesia, and electrolyte injectables.
• ANI Pharmaceuticals: ANI Pharmaceuticals develops, manufactures, and markets generic and branded injectable pharmaceuticals serving US hospital and specialty channels — a smaller-scale but directly comparable injectable-focused competitor.
• B. Braun Medical: B. Braun manufactures IV solutions, injectable drugs, and clinical nutrition products for US hospitals, with a directly comparable injectable portfolio in the institutional channel where American Regent competes.
• Hikma Pharmaceuticals: Hikma is a major manufacturer of generic sterile injectable pharmaceuticals for the US hospital market, with a directly overlapping product portfolio (cardiovascular, electrolyte, and specialty injectables) and similar institutional customer base.
• Amphastar Pharmaceuticals: Amphastar is a US-focused specialty injectable manufacturer with overlapping hospital injectable products and a similar model of combining generic injectables with branded specialty assets — a comparable scale competitor.
• Fresenius Kabi: Fresenius Kabi is one of the largest US suppliers of sterile injectable pharmaceuticals and IV generics, including many of the same therapeutic categories (anesthesia, cardiovascular, electrolytes, nutrition) that American Regent serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmaforce-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaForce Inc.